Tuesday, October 27, 2026

DRAM Prices Set to Double in 2026, Squeezing AI Infrastructure Costs Worldwide

DRAM prices are forecast to rise 125% across 2026, with a 58–63% surge expected in Q2 alone. The shock will hit AI cloud providers globally as memory — not compute — becomes the binding constraint on infrastructure expansion. South Korean and US chipmakers stand to gain while AI startups face compressed runways.

LM Salvado
LM Salvado

May 12, 2026

DRAM Prices Set to Double in 2026, Squeezing AI Infrastructure Costs Worldwide
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The driver is structural. AI model training and inference are hitting memory capacity limits worldwide. As models scale and inference deployments serve millions of requests daily, DRAM — not compute — is becoming the bottleneck on infrastructure expansion.

The impact is unevenly distributed across the global AI economy. Cloud providers in the US, Europe, and Asia Pacific face sharply higher server costs. Memory hardware represents a large share of GPU server bills, and a full-year increase of this scale means materially higher infrastructure capex in H2 2026.1 AI startups burning capital on inference workloads face compressed runways. AI SaaS companies with heavy compute costs may miss earnings estimates as hardware expenses outpace revenue growth.1

The winners are concentrated in East Asia. South Korea's SK Hynix and US-listed Micron — the two dominant suppliers of high-bandwidth and standard DRAM for AI servers — are positioned to outperform as prices climb.1 Samsung, which trails in HBM supply, faces a more complex picture. The pricing surge reinforces South Korea's leverage in global AI supply chains.

This creates a strategic divergence. Companies that lock in long-term supply contracts — or vertically integrate memory procurement — gain a durable cost advantage. Those buying at spot prices through H2 2026 absorb the full surge. For hyperscalers in the US, EU, and China, procurement strategy is now a competitive variable.

The broader AI infrastructure buildout — data centers, power capacity, undersea cables — has dominated capital allocation globally. The DRAM signal narrows the next constraint: it is not bandwidth or energy, but specific memory components at scale.

For AI companies planning capacity through the rest of 2026, memory procurement is no longer a line item. It is a strategic decision that will determine which providers can scale inference profitably — and which cannot.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com